Aardvark Therapeutics, Inc. (NASDAQ:AARD) Short Interest Update

Aardvark Therapeutics, Inc. (NASDAQ:AARD) was the recipient of a large decline in short interest in the month of September. As of September 15th, there was short interest totaling 404,400 shares, a decline of 39.3% from the August 31st total of 665,800 shares. Currently, 3.3% of the shares of the company are short sold. Based on an average daily volume of 120,200 shares, the short-interest ratio is presently 3.4 days. Based on an average daily volume of 120,200 shares, the short-interest ratio is presently 3.4 days. Currently, 3.3% of the shares of the company are short sold.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the company. Jones Trading began coverage on Aardvark Therapeutics in a report on Wednesday. They set a “buy” rating and a $33.00 target price on the stock. Bank of America cut their price objective on shares of Aardvark Therapeutics from $26.00 to $25.00 and set a “buy” rating for the company in a research report on Thursday, August 28th. Stifel Nicolaus assumed coverage on shares of Aardvark Therapeutics in a research note on Monday, September 29th. They set a “buy” rating and a $24.00 price objective on the stock. Royal Bank Of Canada dropped their target price on shares of Aardvark Therapeutics from $20.00 to $19.00 and set an “outperform” rating for the company in a research report on Thursday, August 14th. Finally, Wall Street Zen lowered shares of Aardvark Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, June 14th. Seven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $31.43.

Aardvark Therapeutics Stock Up 4.6%

AARD stock opened at $16.08 on Friday. The company has a fifty day moving average price of $10.87 and a 200-day moving average price of $10.73. Aardvark Therapeutics has a 52-week low of $4.88 and a 52-week high of $19.58.

Aardvark Therapeutics (NASDAQ:AARD) last posted its quarterly earnings data on Wednesday, August 13th. The company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.14).

Insider Buying and Selling

In other Aardvark Therapeutics news, CEO Tien-Li Lee bought 10,000 shares of the firm’s stock in a transaction on Monday, September 15th. The shares were purchased at an average price of $9.66 per share, for a total transaction of $96,600.00. Following the transaction, the chief executive officer directly owned 1,543,384 shares in the company, valued at approximately $14,909,089.44. This trade represents a 0.65% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Nelson Sun bought 6,000 shares of the stock in a transaction dated Tuesday, September 9th. The shares were acquired at an average cost of $8.07 per share, for a total transaction of $48,420.00. Following the completion of the acquisition, the chief financial officer directly owned 105,484 shares of the company’s stock, valued at approximately $851,255.88. This trade represents a 6.03% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 36,000 shares of company stock worth $305,630.

Hedge Funds Weigh In On Aardvark Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Aardvark Therapeutics in the second quarter worth approximately $42,000. Walleye Capital LLC bought a new position in Aardvark Therapeutics during the 1st quarter worth approximately $88,000. New York State Common Retirement Fund acquired a new position in shares of Aardvark Therapeutics in the 2nd quarter worth approximately $99,000. Bank of America Corp DE boosted its stake in shares of Aardvark Therapeutics by 72.9% in the 2nd quarter. Bank of America Corp DE now owns 7,989 shares of the company’s stock valued at $108,000 after purchasing an additional 3,369 shares during the last quarter. Finally, Goldman Sachs Group Inc. bought a new stake in shares of Aardvark Therapeutics in the 1st quarter valued at $153,000.

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.